Tag: Endologix

Endologix’s DETOUR™ System Earns Spot in Local and National Award Forums; Nominated for Prix Galien USA’s Best Medical Technology

Peripheral/Endo by Comments are Disabled

IRVINE, Calif.–(BUSINESS WIRE)– #DETOURSystem–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, proudly announces recent awards and nominations for its groundbreaking DETOUR System. Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral artery, by using conduits routed th

Continue Reading →

Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System

Financial by 0 comments

IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announces that the U. S. Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the DETOUR System, an FDA-designated Breakthrough Device, […]

Continue Reading →

Endologix Announces that Lucas Buchanan Joins Board of Directors

Financial by 0 comments

RVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Lucas Buchanan has been appointed to the Endologix Board of Directors. “We are thrilled to welcome Lucas to our Board of Directors” […]

Continue Reading →

Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease

Peripheral/Endo by 0 comments

IRVINE, Calif.–(BUSINESS WIRE)–Endologix Inc. a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the first patients underwent Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR system, since FDA approval of the system was granted. This marks the official […]

Continue Reading →

Endologix Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting

Peripheral/Endo by 0 comments

The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOURTM System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the 24-month results […]

Continue Reading →

Endologix Receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD

Peripheral/Endo Regulatory by 0 comments

IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the DETOUR System to treat patients with complex peripheral arterial disease (PAD). Over […]

Continue Reading →

Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial

Peripheral/Endo by 0 comments

JAGUAR Study Evaluates ALTO® Compared to Other Commercially Available EVAR Devices IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the completion of the 150th case in the JAGUAR Study. This randomized controlled trial […]

Continue Reading →

Endologix Wins “Medical Device Engineering Breakthrough” Award in 7th Annual MedTech Breakthrough Awards Program

Peripheral/Endo by 0 comments

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced today that its DETOUR™ System has been selected as the winner […]

Continue Reading →

Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)

Peripheral/Endo by 0 comments

The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment […]

Continue Reading →

Endologix Receives FDA Approval of PMA Supplement for AFX2 System

Peripheral/Endo Regulatory by 0 comments

The AFX2 Endovascular AAA System integrates anatomical fixation with an advanced delivery system to facilitate treatment of patients with abdominal aortic aneurysm (AAA). IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company, dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, today announced that it […]

Continue Reading →
1 2 3 4 … 10